Triple Negative Breast Cancer Survival Rates by Stage

Triple negative breast cancer survival rates by stage - The pathology report you might say that breast cancer cells tested negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 (HER2-). Testing negative for the third cancer facility is triple-negative.

A negative result means that the cancer growth is not supported by the hormone estrogen and progesterone, or by the presence of too many HER2 receptors. Therefore, triple negative breast cancer does not respond to hormonal therapy (such as tamoxifen or aromatase inhibitors) or therapy that targets HER2 receptors, such as Herceptin (chemical name: trastuzumab). However, other medications may be used to treat triple-negative breast cancer.

About 10-20% of breast cancer more than one of every 10-found to be triple-negative. For doctors and researchers, there is intense interest in finding new drugs that can treat this type of breast cancer. A preliminary study to try to figure out whether certain medications can interfere with the process that led to a triple-negative breast cancer to grow.
Triple Negative Breast Cancer Survival Rates by Stage

How the Triple-negative Breast Cancer behaves and looks

To understanding triple-negative breast cancer, it is important to understand the receptor, which is a protein found inside and on the surface of the cell receptor proteins. This is the "eyes" and "ears" of the cell, receive messages from a substance in the blood stream and then tell cells what to do.

Hormone receptors in and on the surface of cells of a healthy breast received a message from the hormone estrogen and progesterone. Hormones attach to receptors and provide clues that help the cells continue to grow and function properly. Most, but not all, breast cancer cells have Hormone receptors as well. Approximately 2 out of 3 women have breast cancer who test positive for hormone receptors. (For the complete explanation, see the Hormone Receptor Status.)

A smaller percentage of breast cancer about 20-30%-have too many HER2 receptors. In normal breast cells, healthy, HER2 receptors receive signals that stimulate their growth. With too much HER2 receptors, however, breast cancer cells grow and divide too quickly. (For the complete explanation, see HER2 Status page.)
See also: Symptoms of Lung Cancer on Different Stages in Men and Women
hormonal therapies and HER2-targeted therapies work to interfere with the effects of the hormone and HER2 in breast cancer, which can help slow or even halt the growth of breast cancer cells.

About 10-20% of the breast cancer test negative for HER2 and hormone receptor both in the laboratory, which means they are triple-negative. Because hormones do not support its growth, the cancer is unlikely to respond to hormonal therapy, including tamoxifen, Arimidex (chemical name: anastrozole), Aromasin (chemical name: exemestane), Femara (letrozole: chemical name) and Faslodex (fulvestrant: chemical name). triple-negative breast cancer is also unlikely to respond to drugs that target HER2, Herceptin as (chemical name: trastuzumab) or Tykerb (lapatinib: chemical name).

In addition, triple-negative breast cancer:

Tend to be more aggressive than other types of breast cancer. Research has shown that triple-negative breast cancer is more likely to spread beyond the breast and more likely to recur (come back) after treatment. This risk appears to be greatest in the first few years after treatment. For example, a study of more than 1,600 women in Canada, published in 2007 found that women with triple-negative breast cancer at higher risk of experiencing a relapse of breast cancer out — but only for the first 3 years. Other studies have reached the same conclusion. As the years passed, the risk of triple-negative breast cancer recurring became similar to the level of risk for different types of breast cancer.

How Fast does Triple Negative Cancer Grow

The five-year survival rates also tend to be lower for triple-negative breast cancer. A 2007 study of more than 50,000 women with all stages of breast cancer found that 77% of women with triple-negative breast cancer survive at least 5 years, compared to 93% of women with other types of breast cancer. Another study of more than 1,600 women published in 2007 found that women with triple-negative breast cancer have a higher risk of death within 5 years of diagnosis, but not after that time period. Recurrence and survival figures in this study and others that the average for all women with triple-negative breast cancer. Factors such as grades and stages of breast cancer will affect the prognosis of individual women.

The class is likely to be higher than other types of breast cancer. The higher the class, the fewer cancer cells resemble normal breast cells healthy in appearance and their patterns of growth. On a scale of 1 to 3, triple-negative breast cancer often class 3.
See also: What Kind Of Cancer Does Michael Stanley Have?
Usually is a type of cell called a "basal-like". "Basal-like" means that the cells of the basal cell resemble the lining of a breast duct. This is a new subtype of breast cancer that researchers have identified a gene analysis technology. as the type of breast cancer, basal-like cancer can be linked to family history, or they can occur without obvious family links. basal-like cancer tends to be more aggressive, higher grade cancer such as triple-negative breast cancer. It is believed that triple-negative breast cancer from the basal cell-like type.

This can be irritating and even scary feeling to know that you have a form of breast cancer who (1) are often more aggressive than other types and (2) is not a good candidate for hormonal therapy and treatments such as Herceptin. But triple-negative breast cancer can be treated with chemotherapy and radiation therapy, and new treatments such as PARP-inhibitor shows promise. Researchers pay much attention for triple-negative breast cancer and work to find new and better ways to treat it. "This is a very hot area of research in the field of breast cancer," said George Sledge, M.D., medical oncologists and a member of Professional Advisory Board.